Amid the geopolitical turbulence, a piece of welcome news emerged from the world of medicine. Pfizer announced that its experimental breast cancer drug, atirmociclib, significantly reduced the risk of disease progression in a mid-stage clinical trial. More than 90% of patients began the drug within three months of stopping their previous cancer treatment. While further trials will be needed, the results offer hope for patients with few remaining options.
Walter Murrow
March 18, 2026
0
1